[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334461-105":59,"doc-detail-334461-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tissue-predisposition-to-cancer-driver-mutations","Tissue-Predisposition to Cancer Driver Mutations","","Driver mutations underpin cancer initiation by providing competitive fitness advantages, leading to higher mutation frequencies in premalignant tissues than baseline rates. Selection pressures then act on a molecular niche formed by each tissue, shaping whether cancer driver mutations expand or fail to propagate. The observed distribution is tissue-specific, exemplified by APC in colorectal cancer and BCR-ABL1 fusion in chronic myeloid leukemia. A mechanistic framework explains how tissue features, from epigenetics to viral transposable elements, enable tissue-specific selection of driver mutations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tissue-predisposition-to-cancer-driver-mutations/334461/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tissue-predisposition-to-cancer-driver-mutations/334461.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are driver mutations and why are they expected to appear more often in premalignant tissue?","Question",{"text":112,"@type":113},"Driver mutations are those that confer a competitive fitness advantage. Because of this advantage, their frequency in premalignant tissue is expected to exceed the basal mutation rate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does tissue specificity influence cancer driver mutations?",{"text":117,"@type":113},"Each tissue acts as its own niche, creating molecular selective pressure. This pressure can favor the propagation of certain mutations in a tissue-specific manner.",{"name":119,"@type":110,"acceptedAnswer":120},"What examples illustrate the non-uniform distribution of driver mutations across tissues?",{"text":121,"@type":113},"Mutations in APC are particularly frequent in colorectal cancer, and the BCR-ABL1 fusion mutation occurs in 99% of chronic myeloid leukemia patients but is rarely found in solid tumors. Germline BRCA1 also predisposes to ovarian and breast cancer, while TP53 shows frequency bias toward specific tissues like lung and colon.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334461,1790064068,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","cells  \nReview  \nTissue-Predisposition to Cancer Driver Mutations  \nLuriano Peters, Avanthika Venkatachalam  and Yinon Ben-Neriah *  \nCitation: Peters, L.; Venkatachalam, A.; Ben-Neriah, Y. Tissue-Predisposition to Cancer Driver Mutations. Cells 2024, 13, 106. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells13020106](10.3390/cells13020106)  \nAcademic Editors: Stephen Yarwood and Tuula Kallunki  \nReceived: 8 December 2023  \nRevised: 2 January 2024  \nAccepted: 3 January 2024  \nPublished: 5 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nLautenberg Center for Immunology and Cancer Research, Institute for Medical Research (IMRIC), The Faculty of Medicine, Hebrew University of Jerusalem, P.O. Box 12272, Jerusalem 91120, Israel;  \n[luriano.peters@mail.huji.ac.il](luriano.peters@mail.huji.ac.il) (L.P.); avanthik.venkatachal@mail.huji.ac.il (A.V.)  \n* [Correspondence: yinonb@ekmd.huji.ac.il](Correspondence: yinonb@ekmd.huji.ac.il)  \nAbstract: Driver mutations are considered the cornerstone of cancer initiation. They are defined as mutations that convey a competitive fitness advantage, and hence, their mutation frequency in premalignant tissue is expected to exceed the basal mutation rate. In old terms, that translates to “the survival of the fittest” and implies that a selective process underlies the frequency of cancer driver mutations. In that sense, each tissue is its own niche that creates a molecular selective pressure that may favor the propagation of a mutation or not. At the heart of this stands one of the biggest riddlesin cancer biology: the tissue-predisposition to cancer driver mutations. The frequency of cancer driver mutations among tissues is non-uniform: for instance, mutations in APC are particularly frequent in colorectal cancer, and 99% of chronic myeloid leukemia patients harbor the driver BCR-ABL1 fusion mutation, which is rarely found in solid tumors. Here, we provide a mechanistic framework that aims to explain how tissue-specific features, ranging from epigenetic underpinnings to the expression of viral transposable elements, establish a molecular basis for selecting cancer driver mutations in atissue-specific manner.  \nKeywords: cancer evolution; driver mutations; selective pressure  \n1. Introduction  \nWhile rediscovering Mendel’s genetics, the term “mutation” was coined by Hugo de Vries, in 1901, to explain the apparent differences of progeny from its direct parent generation. Mutationists like de Vries did not reject evolution but believed that it takes place in large and sudden leaps which are entirely driven by genetic events. In contrast, Charles Darwin’s gradualism assumed that small variations occur throughout a long period of time, and the driving force is external factors leading to natural selection [1] . Natural selection, however, positively selects beneficial traits and may explain the survival of the fittest but not how the fittest was created. Darwin’s theory was therefore insufficient to explain the ongoing variation within a population [2] . Nevertheless, even without the Modern Synthesis [3]—a modern interpretation encompassing Darwin’s and Mendelian genetics—a cancer biologist would reconcile both hypotheses and fuse them based on their experimental experience, as many aspects of cancer follow both Darwin’s and de Vries’assumptions. Mutations may bring along constant and instant phenotypic changes that natural selection can act on. This evolutionary concept diverges experimentally into two scientific questions: first, how do genetic variations occur in the first place, and second, how are these variations selected for? While the last decades have s","cbCaigr2gGnMy08j","https://ap.wps.com/l/cbCaigr2gGnMy08j","pdf",1938780,15,"English","# Introduction","[{\"question\":\"What are driver mutations and why are they expected to appear more often in premalignant tissue?\",\"answer\":\"Driver mutations are those that confer a competitive fitness advantage. Because of this advantage, their frequency in premalignant tissue is expected to exceed the basal mutation rate.\"},{\"question\":\"How does tissue specificity influence cancer driver mutations?\",\"answer\":\"Each tissue acts as its own niche, creating molecular selective pressure. This pressure can favor the propagation of certain mutations in a tissue-specific manner.\"},{\"question\":\"What examples illustrate the non-uniform distribution of driver mutations across tissues?\",\"answer\":\"Mutations in APC are particularly frequent in colorectal cancer, and the BCR-ABL1 fusion mutation occurs in 99% of chronic myeloid leukemia patients but is rarely found in solid tumors. Germline BRCA1 also predisposes to ovarian and breast cancer, while TP53 shows frequency bias toward specific tissues like lung and colon.\"}]","Tissue-Predisposition to Cancer Driver Mutations | PDF",1790006751,38]